Stockscreener 앱 받기
3.16
2.17%
-0.07
시간 외 거래:
3.28
0.12
+3.80%
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Atyr Pharma: Q1 Earnings Snapshot - The Washington Post
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update - Stock Titan
Daily Market Movement: Atyr Pharma Inc (ATYR) Sees a -9.78 Decrease, Closing at 3.23 - DWinneX
aTyr Pharma, Inc.'s (NASDAQ:ATYR) Path To Profitability - simplywall.st
Wells Fargo & Company MN Invests $383,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
FY2026 EPS Estimates for Atyr PHARMA Lowered by Analyst - Defense World
Atyr Pharma Inc [ATYR] Records 200-Day SMA of $2.90 - knoxdaily.com
There is no doubt that Atyr Pharma Inc (ATYR) ticks all the boxes. - Sete News
How should investors view Atyr Pharma Inc (ATYR)? - uspostnews.com
JPMorgan Chase & Co. Boosts Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Preclinical Data for NRP2-Targeting - GlobeNewswire
When Will aTyr Pharma, Inc. (NASDAQ:ATYR) Turn A Profit? - Yahoo
Leerink Partners gives an Outperform recommendation for Atyr Pharma Inc (ATYR) - knoxdaily.com
aTyr Pharma (ATYR) Reveals Promising Preclinical Data on Cancer Treatment | ATYR Stock News - GuruFocus
aTyr Pharma presents preclinical data on ATYR2810 at AACR - TipRanks
Market Watch Highlights: Atyr Pharma Inc (ATYR) Ends on an Downturn Note at 3.27 - DWinneX
Atyr Pharma Inc (NASDAQ: ATYR) Stock: More Upside Ahead? - Marketing Sentinel
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Breakthrough: Novel Antibody ATYR2810 Extends Survival in Aggressive Brain Cancer Trial - Stock Titan
Geode Capital Management LLC Buys Shares of 891,407 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Director Gross Jane A acquire 3,750 shares of Atyr Pharma Inc [ATYR] - knoxdaily.com
Analytical Lens: Exploring Atyr Pharma Inc (ATYR)’s Financial Story Through Ratios - DWinneX
Atyr PHARMA (ATYR) to Release Quarterly Earnings on Thursday - Defense World
Watch this stock’s price performance: Atyr Pharma Inc (NASDAQ:ATYR) - uspostnews.com
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock By Investing.com - Investing.com Canada
Solid Biosciences (NASDAQ:SLDB) versus Atyr PHARMA (NASDAQ:ATYR) Head to Head Comparison - Defense World
Atyr Pharma Inc (ATYR) receives an Outperform rating from Leerink Partners - knoxdaily.com
Cantor maintains Overweight on aTyr Pharma stock ahead of trials By Investing.com - Investing.com Canada
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
Raymond James Financial Inc. Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Makes New $319,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
American Century Companies Inc. Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR) - The AM Reporter
Atyr PHARMA INC (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
US High Growth Tech Stocks to Watch in 2023 - simplywall.st
aTyr Pharma to Participate in April Investor Conferences - GlobeNewswire
Biotech Innovator aTyr Pharma Sets Key Investor Meetings at Premier Healthcare Conferences - Stock Titan
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - marketscreener.com
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
0.88%
2.05%
자본화:
|
볼륨(24시간):